The 5 Most Interesting Analyst Questions From AdaptHealth's Q2 Earnings Call

AdaptHealth’s Q2 results were met with a notably positive market reaction, as investors looked past flat year-on-year sales to focus on operational progress and margin improvement. Management attributed performance to its recent success in non-acquired revenue growth, especially through accelerating momentum in its Sleep and Respiratory Health segments. CEO Suzanne Foster highlighted improvements in patient setup times and order intake processes, which led to higher volumes in core lines. Additionally, profitability initiatives—such as standardizing operations and leveraging technology—drove operating margin expansion despite segment-level headwinds.

Is now the time to buy AHCO? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From AdaptHealth’s Q2 Earnings Call

• Eric Coldwell (Baird) asked about the revenue ramp, pricing, and growth expectations of the new capitated contract. CFO Jason Clemens clarified that $200 million annual revenue is a conservative estimate, ramping through 2026, with additional upside possible from expanded sales coverage.

• Philip Chickering (Deutsche Bank) questioned the adjusted EBITDA guidance reduction. Clemens explained that the drop was driven by delayed payer rate negotiations and infrastructure investment for the new contract, not by asset divestitures.

• Chickering (Deutsche Bank) followed up on market share in Sleep Health relative to competitors like ResMed. Clemens pointed to a 3% increase in starts and expects further improvement as operational changes take full effect in coming quarters.

• Brian Tanquilut (Jefferies) queried management’s approach to upcoming CMS competitive bidding and diabetes pricing. CEO Suzanne Foster acknowledged uncertainty but stressed AdaptHealth’s scale and ongoing efficiency efforts as advantages in navigating reimbursement pressure.

• Unidentified Analyst (RBC Capital Markets) asked about M&A opportunities and leverage tolerance. Foster and Clemens said M&A remains disciplined and focused on core segments, with any deals likely self-funded and not increasing leverage.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will track (1) the pace and operational execution of the new capitated contract rollout, (2) the impact of automation and standardization on margin trends, and (3) outcomes of key CMS policy decisions and payer negotiations. The trajectory of Diabetes Health segment recovery and ongoing industry consolidation will also be critical signposts for AdaptHealth’s growth and profitability.

AdaptHealth currently trades at $9.59, up from $9.13 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.